Perspective Therapeutics, Inc. (CATX): Total Liabilities
$59.94M
As of 2025-12-31
$68.16M
As of 2026-06-30
+159.0%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.94M | +18.9% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $50.43M | +122.1% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $22.71M | +558.5% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $3.45M | n/a | 2024-03-28, Balance as of period end |
| 2022-06-30 | $3.16M | +5.0% | 2022-09-28, Balance as of period end |
| 2021-06-30 | $3.01M | +1.1% | 2022-09-28, Balance as of period end |
| 2020-06-30 | $2.98M | +70.8% | 2021-09-27, Balance as of period end |
| 2019-06-30 | $1.74M | -28.2% | 2020-09-25, Balance as of period end |
| 2018-06-30 | $2.42M | +45.5% | 2019-09-27, Balance as of period end |
| 2017-06-30 | $1.67M | -2.0% | 2018-09-26, Balance as of period end |
| 2016-06-30 | $1.70M | -23.4% | 2017-09-28, Balance as of period end |
| 2015-06-30 | $2.22M | -14.4% | 2016-09-09, Balance as of period end |
| 2014-06-30 | $2.59M | +53.5% | 2015-09-14, Balance as of period end |
| 2013-06-30 | $1.69M | +0.1% | 2014-09-29, Balance as of period end |
| 2012-06-30 | $1.69M | +17.5% | 2013-09-30, Balance as of period end |
| 2011-06-30 | $1.44M | n/a | 2012-10-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | $59.94M | +18.9% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $57.16M | -44.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Damora Therapeutics, Inc. (DMRA) | 2025-12-31 | $20.15M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $697.32M | +10.4% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $15.65M | +5.9% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $50.84M | -40.8% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $32.02M | +37.2% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $201.25M | +38.2% |
Compare CATX, ARCT, NATR, DMRA side by side · Screen every company in Pharmaceutical Preparations ↗